ES2526147T3 - Ésteres de metronidazol para el tratamiento de la rosácea - Google Patents

Ésteres de metronidazol para el tratamiento de la rosácea Download PDF

Info

Publication number
ES2526147T3
ES2526147T3 ES11728011.5T ES11728011T ES2526147T3 ES 2526147 T3 ES2526147 T3 ES 2526147T3 ES 11728011 T ES11728011 T ES 11728011T ES 2526147 T3 ES2526147 T3 ES 2526147T3
Authority
ES
Spain
Prior art keywords
rosacea
treatment
metronidazole esters
metronidazole
esters
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11728011.5T
Other languages
English (en)
Inventor
Jean-Guy Boiteau
Jean-Michel Linget
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Galderma Research and Development SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Research and Development SNC filed Critical Galderma Research and Development SNC
Application granted granted Critical
Publication of ES2526147T3 publication Critical patent/ES2526147T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/91—Nitro radicals
    • C07D233/92—Nitro radicals attached in position 4 or 5
    • C07D233/94—Nitro radicals attached in position 4 or 5 with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to other ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compuesto seleccionado a partir del compuesto de fórmula (I) siguiente:**Fórmula** y una de sus sales farmacéuticamente aceptables.

Description

imagen1
imagen2
imagen3
imagen4
imagen5

Claims (1)

  1. imagen1
ES11728011.5T 2010-06-29 2011-06-29 Ésteres de metronidazol para el tratamiento de la rosácea Active ES2526147T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1055244A FR2961811B1 (fr) 2010-06-29 2010-06-29 Esters de metronidazole pour traiter la rosacee
FR1055244 2010-06-29
PCT/EP2011/060925 WO2012001055A1 (en) 2010-06-29 2011-06-29 Metronidazole esters for treating rosacea

Publications (1)

Publication Number Publication Date
ES2526147T3 true ES2526147T3 (es) 2015-01-07

Family

ID=42797343

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11728011.5T Active ES2526147T3 (es) 2010-06-29 2011-06-29 Ésteres de metronidazol para el tratamiento de la rosácea

Country Status (7)

Country Link
US (1) US8796325B2 (es)
EP (1) EP2588461B1 (es)
JP (1) JP2013529669A (es)
CA (1) CA2801991A1 (es)
ES (1) ES2526147T3 (es)
FR (1) FR2961811B1 (es)
WO (1) WO2012001055A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2991682T3 (en) * 2013-04-30 2017-07-10 Claus Selch Larsen PRODRUGS OF NAPROXEN AND DICLOFENAC
CN105348200B (zh) * 2015-12-23 2018-09-25 武汉武药制药有限公司 一种甲硝唑合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0127274A3 (en) * 1983-03-25 1987-05-20 The Upjohn Company Esters of metronidazole and compositions containing them
IL142037A0 (en) * 2001-03-15 2002-03-10 Agis Ind 1983 Ltd Pharmaceutical compositions containing a non-steroidal anti-inflammatory drug
US8853247B2 (en) * 2007-11-02 2014-10-07 Nektar Therapeutics Oligomer-nitroimidazole anti-infective conjugates

Also Published As

Publication number Publication date
US20130197048A1 (en) 2013-08-01
FR2961811B1 (fr) 2012-07-06
JP2013529669A (ja) 2013-07-22
WO2012001055A1 (en) 2012-01-05
US8796325B2 (en) 2014-08-05
EP2588461A1 (en) 2013-05-08
FR2961811A1 (fr) 2011-12-30
EP2588461B1 (en) 2014-11-05
CA2801991A1 (en) 2012-01-05

Similar Documents

Publication Publication Date Title
ES2634490T3 (es) Derivados de ácido napht-2-ylacetico para tratar el sida
ES2643827T3 (es) Procedimiento para la regulación del perfil del espesor de películas de soplado
ES2659758T3 (es) Antagonistas de receptores de 5-HT3
ES2528026T3 (es) Sales de oxalato de ivabridina cristalino y polimorfos de los mismos
ES2502472T3 (es) Composición adhesiva para su uso en un inmunosensor
ES2661582T3 (es) Efecto antiinflamatorio de la celulosa microfibrilada
CL2012001911A1 (es) Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa.
CR20160007A (es) Nuevos compuestos triciclicos
CR20120418A (es) Inhibidores de virus flaviviridae
CR20120397A (es) Inhibidores del virus de la hepatitis c
ES2525918T3 (es) Proceso para la fabricación de Nicorandil
CR20170159A (es) Nuevos compuestos tricíclicos
ES2641862T3 (es) Proceso para la elaboración de inhibidores de CCR3
GT200600394A (es) Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis.
ES2488407T3 (es) Preparación farmacéutica que contiene lipasa de origen bacteriano
GT201300214A (es) Moduladores de los receptores de hormonas nucleares
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
AR102981A1 (es) Inhibidores de la necrosis celular y métodos de preparación de los mismos
CL2017000682A1 (es) Compuestos novedosos de imidazopiridazina y su uso.
ES2485373T3 (es) Compuestos que actúan en múltiples receptores de prostaglandina proporcionando una respuesta anti-inflamatoria general
ES2650914T3 (es) Sales de adición de ácidos de 5alfa-hidroxi-6beta-[2-(1H-imidazol-4-il)etilamino]colestan-3beta-ol
CL2012003341A1 (es) Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades.
ES2526147T3 (es) Ésteres de metronidazol para el tratamiento de la rosácea
ES2611776T3 (es) Uso de sales de tungsteno (VI) para el tratamiento de la esterilidad femenina en mamíferos no diabéticos
CL2012002452A1 (es) Procedimientos para la preparacion de 2-(ciclohexilmetil)-n-{2-[(2s)-1-metilpirrolidin-2-il] etil}-1,2,3,4-tetrahidroisoquinolin-7-sulfonamida; uno de sus compuestos interemdiarios; y la preparacion del mismo.